Migraine Trigger Surprisal Model May Help Predict Attacks

Dawn C. Buse, PhD, FAHS, says novel research published in Headache® is empowering and exciting for the behavioral modification aspect of migraine treatment There is little known about specific environmental or behavioral interactions that could trigger a headache attack in a prone individual. But a study recently published in Headache® provides new insight into the relationship between potential migraine triggers and headache attacks.  Dawn C. Buse, PhD, FAHS, reviewed this article for the American Headache Society. She says the research found that a trigger surprisal model may be useful for determining headache risks caused by a diverse set of triggers...

Preventive Migraine Treatment: How to Counsel Patients

Duren Michael Ready, MD, FAHS, discusses how to work with patients to achieve the best preventive treatment results Duren Michael Ready, MD, FAHS, is the director of the Headache Clinic at Baylor Scott & White in Temple, Texas. Dr. Ready spoke during the 2018 Scottsdale Headache Symposium about how to counsel patients about their preventive migraine treatment. Watch the full interview here:  https://youtu.be/jid0IkoXG5c Dr. Ready says that it’s important to educate patients about why they are taking a certain medication. They may, for example, feel hesitant to take an anti-hypertensive medication if they don’t have high blood pressure. Advising them...

Migraine Progression Risk Factors: A Systematic Review

New research published in Headache® identifies risk factors for the progression of episodic migraine to chronic migraine.  A range of risk factors have been identified for the new onset of chronic migraine (CM) or related chronic headache diagnoses among people with episodic migraine (EM) according to a systematic review published in Headache®. Dawn C. Buse, PhD, FAHS; Richard B. Lipton, MD, FAHS; and colleagues identified and summarized studies that reported on these migraine progression risk factors. Then, they determined the strength of the evidence behind them.  Buse says she hopes that healthcare professionals and people with migraine find the review...

FDA Approves Acute Migraine Treatment for Adults

On October 11, 2019, the FDA approved lasmiditan (REYVOW™) for the acute treatment of migraine, with or without aura, in adults. This oral treatment is the first FDA-approved medicine in a new class of acute migraine treatment (serotonin (5-HT)1F receptor agonists).  Two separate Phase III, placebo-controlled studies evaluated the safety and efficacy of lasmiditan. Both studies found that patients who were administered lasmiditan reported higher levels of pain freedom. They also reported freedom from most bothersome patient-selected symptoms after 2 hours. Lasmiditan’s adverse effects were most frequently found to include dizziness, fatigue, paresthesia, sedation, nausea and/or vomiting, and muscle weakness....

Burden of Migraine Affects Family, Career

A new CaMEO Study analysis demonstrates the wide-reaching impact of migraine on the partners, children, and jobs of people who live with it. The burden of migraine has a well-recognized effect on those who live with the disease. But there is also a ripple effect that affects their careers and family life, as well. “We have long known that living with migraine, a chronic, painful, unpredictable and often disabling disease, can have wide and far-reaching effects on every aspect of life that someone holds dear,” says Dawn Buse, PhD, FAHS. “People with migraine tell us these stories on a daily...

Next Generation Migraine Therapies – Miami

The Next Generation Migraine Therapies (NGMT) initiative is a comprehensive program designed to provide a multi-faceted approach to migraine education offered at no cost to healthcare providers including neurologists, primary care physicians and advanced practice providers. Brought to you by the American Headache Society, the program covers topics around the diagnosis and treatment of migraine, and updates on the latest science around the disease. Through a mix of regional in-person workshops, NGMT is designed to engage participants through didactic and interactive case study workshops. Register at no cost to attend our Miami event here.

  • Diagnosis and treatment
    • Acute and Preventative treatment options
    • What works well and what are the unmet needs?
    • Risks for migraine progression
  • The latest science
    • State of the art therapeutic options
    • Multi format administration options
    • CGRP receptors as a target for small molecules: GPANTs
    • Immunology, antibodies, and monoclonal antibodies
    • Neuromodulation update
  • Answer questions such as
    • How can peripherally acting drugs treat migraine?
    • What do I need to know about monoclonal antibodies that treat migraine?
    • How do I best identify appropriate patients for the appropriate therapeutic option?
    • What do I need to know to identify appropriate patients for these emerging therapies?

Register Now

Pediatric Migraine Camp Benefits Patients and Parents

A paper published in Headache® details how a youth camp helps teens and their families cope with pediatric migraine Teenage patients and their parents can benefit from one-day intervention in the form of a pediatric migraine camp, according to a paper published in Headache®.  Christina L. Szperka, MD, MSCE, FAHS of the Children’s Hospital of Philadelphia and colleagues developed the Migraine Youth Camp. The camp a comprehensive, one-day intervention aimed at providing expanded headache education. It also teaches coping strategies for living with chronic pain and encouraging the development of a supportive community for adolescents living with chronic headache disorders,...

Treating Pediatric Migraine

Lauren Doyle Strauss, DO, FAHS, talks about how to make children living with migraine more comfortable Lauren Doyle Strauss, DO, FAHS, of Wake Forest Baptist Health in Winston-Salem, North Carolina, and Brenner Children's Hospital, recently spoke about what physicians should think about when treating pediatric migraine treatment. Watch the full interview from the 2018 Scottsdale Headache Symposium here: When she trains someone without pediatric headache experience, Strauss underscores the difference between pediatric visits and those with adult patients.  https://www.youtube.com/watch?v=Zs3xVdhJ4QM&t=31s “We are not just treating pediatric migraine," she says. "We're also treating the child's parents or guardians, so our visit is...

Advocating for Patients with Migraine: Q&A

Amaal Starling, MD, FAHS, discusses how doctors also function as migraine warriors  Healthcare providers can be some of the biggest and best advocates for their patients. But many doctors are unsure of how they can get started advocating for patients with migraine.  Amaal Starling, MD, FAHS, is an assistant professor at Mayo Clinic in Scottsdale, Arizona. We recently spoke with Starling about how providers can get involved more with advocacy efforts—as well as how their daily responsibilities already qualify them as migraine warriors. https://youtu.be/2EMv_O_hSj4 How do you explain the value of advocating for patients with migraine in clinical practice? I...

OTC Migraine Treatment: Q&A

Jessica Ailani, MD, FAHS, discusses working with patients and getting honest answers about their OTC migraine treatment strategies Headache treatment plans often involve over-the-counter (OTC) medicines. But there are several things for healthcare providers to consider about OTC migraine treatment when working with patients. This is especially true when it comes to misconceptions about safety and efficacy. OTC medications carry the potential to cause harm, and their unrestricted use can also lead to medication-overuse headache. This can complicate treatment.  Jessica Ailani, MD, FAHS, is the director of the MedStar Georgetown Headache Center at MedStar Georgetown University Hospital in Washington, D.C....